Hospital Stocks Fall Up to 7%: Why Max, Apollo and Fortis Are Sliding After Supreme Court's 16% Drug Margin Remark

Hospital stocks came under heavy selling on Wednesday. Max Healthcare Institute fell as much as 6.78% to Rs 915.50 on the NSE, Fortis Healthcare slid up to 6.05% to Rs 772.30 and Apollo Hospitals Enterprise dropped up to 5.62% to Rs 8,172. Around 11 AM, all three were still down between 4.1% and 5.3%.

The selling in hospital stocks was not limited to the big three. HealthCare Global Enterprises and Narayana Hrudayalaya also traded lower. The trigger was a pointed Supreme Court hearing on drug pricing held a day earlier.

Click Here – Get Free Investment Predictions

Why Are Hospital Stocks Falling Today?

Hospital stocks are falling because the Supreme Court on 29 September 2026 questioned the steep markups private hospitals charge on medicines and suggested capping margins at 16%. A bench including Justice Sandeep Mehta described a 10-fold markup on some cancer drugs as carnage, citing a medicine with an MRP of Rs 27,000 that is supplied to retailers for about Rs 2,700.

The court noted that the Drugs (Prices Control) Order, or DPCO, already provides a 16% margin, but only for scheduled essential medicines. It asked why that margin could not apply to all drugs. The Solicitor General said the main gainer in such cases is the private hospital rather than the drugmaker, and agreed the issue needs attention. The bench also asked the Centre to examine hospitals that require patients to buy medicines only from in-house pharmacies.

Here is how the major hospital stocks were trading around 11 AM on 30 September 2026, based on exchange data.

Stock	Price (Rs)	Change (%)	Day Low (Rs)	P/E (TTM)
Max Healthcare	941.80	-4.10	915.50	65.73
Apollo Hospitals	8,203.00	-5.27	8,172.00	57.61
Fortis Healthcare	779.50	-5.17	772.30	57.76
HealthCare Global	675.80	-3.95	668.50	-
Narayana Hrudayalaya	1,768.40	-1.20	1,730.10	-

Why a Drug Margin Cap Worries Hospital Investors

Pharmacy sales are an important profit stream for large hospital chains, particularly for expensive oncology and specialty drugs. When a hospital buys a medicine near the price to retailer and sells it close to MRP, the gap flows straight into earnings. A 16% cap above the purchase price would shrink that gap sharply on high-value drugs.

That is why hospital stocks reacted so quickly. Hospital chains that earn a larger share of EBITDA from in-house pharmacy markups face the most near-term margin pressure if the suggestion becomes policy. Oncology-focused operators are especially exposed, given how the court singled out cancer medicines.

Screen hospital stocks by valuation and margins on the Univest Screener

Max Healthcare, Apollo and Fortis Share Price Moves

Max Healthcare share price took the heaviest hit among the large chains, falling 6.78% at the day's low. At about 66 times trailing earnings, Max carries one of the richer valuations in the sector, which can amplify selling on regulatory news.

Apollo Hospitals share price had already been under pressure, losing about 9.1% over the past five sessions, according to market data. Apollo also runs one of India's largest pharmacy networks, so drug pricing headlines tend to weigh on it.

Fortis Healthcare share price slid 6.05% at its low. Fortis had been one of the stronger performers in the sector over the past year on steady bed additions and margin gains, so part of the fall reflects profit booking.

Download the Univest iOS App or Univest Android App to track hospital stocks and set alerts for regulatory news.

What Hospital Stocks Investors Should Watch Next

The next hearing on 12 October 2026 is the key date for hospital stocks. The Centre is expected to respond on whether a uniform margin cap is workable, and the court may also address mandatory in-house pharmacy purchases.

Investors should keep perspective. This is judicial scrutiny, not a notified rule, and any eventual framework could be narrower or take time to apply. Patented medicines currently sit outside the DPCO's scope. Demand for private hospital care, occupancy levels and bed expansion plans are unchanged by the hearing.

Key Risks for Hospital Stocks

• Regulatory action: A formal margin cap on medicines could cut pharmacy profits and overall EBITDA margins.
• Pricing scrutiny: Earlier in 2026, a Parliamentary panel suggested benchmarking hospital room charges, showing growing policy focus on hospital pricing.
• Valuation: Large hospital stocks trade at 57 to 66 times trailing earnings, leaving little cushion for negative news.
• Headline volatility: Court hearings and policy comments can trigger sharp one-day moves before any final outcome.

Bottom Line on Hospital Stocks

Hospital stocks fell up to 7% after the Supreme Court floated a uniform 16% margin on medicines, with Max Healthcare, Fortis and Apollo leading the decline. The proposal is not final, and the 12 October hearing will show how far the Centre and the court want to go. Long-term demand remains intact, but regulatory risk is now part of the story, so consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Hospital Stocks

Why are hospital stocks falling today?

Ans. Hospital stocks fell up to 7% on 30 September 2026 after the Supreme Court, on 29 September, criticised steep markups on cancer drugs sold by hospitals and suggested a uniform 16% margin on all medicines. Investors worry that a cap could squeeze hospital pharmacy profits.

How much did Max Healthcare, Apollo and Fortis fall?

Ans. Max Healthcare share price fell as much as 6.8% to Rs 915.50, Fortis Healthcare share price dropped up to 6.05% to Rs 772.30 and Apollo Hospitals share price slid up to 5.62% to Rs 8,172 on the NSE on 30 September 2026.

What did the Supreme Court say about hospital drug prices?

Ans. The Supreme Court called a 10-fold markup on some cancer medicines carnage and cited a drug with an MRP of Rs 27,000 supplied to retailers at about Rs 2,700. It suggested applying the 16% margin prescribed under the DPCO to all medicines and asked the Centre to respond.

Is the 16% drug margin cap final?

Ans. No. The 16% margin is a suggestion made during the hearing, not a ruling or notified rule. The Supreme Court has posted the matter for further hearing on 12 October 2026 and will consider the Centre's response.

Why does a drug margin cap matter for hospitals?

Ans. Pharmacy sales are a meaningful source of profit for large hospital chains, especially for high-value oncology drugs. A cap on markups could reduce pharmacy margins and, in turn, overall EBITDA margins.

When is the next Supreme Court hearing on drug margins?

Ans. The Supreme Court has listed the matter for further hearing on 12 October 2026. Hospital investors will watch the Centre's response and any direction on in-house pharmacy practices.

Should investors sell hospital shares after the fall?

Ans. That depends on your holding period and risk appetite. Demand for quality private healthcare remains strong, but regulatory risk has risen, so consult a SEBI-registered advisor before making changes.